The objectives of this study are to evaluate the safety of IW-9179 in patients with diabetic gastroparesis (DGP) and the effect of treatment on the cardinal symptoms of DGP.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
90
Ironwood Investigational Site
Birmingham, Alabama, United States
Exploratory Endpoint - Daily Severity of Patient-reported Diabetic Gastroparesis Symptoms
Time frame: Change from baseline: Treatment Period (weeks 1-4) compared with 2-week (baseline) Pretreatment Period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ironwood Investigational Site
Dothan, Alabama, United States
Ironwood Investigational Site
Tucson, Arizona, United States
Ironwood Investigational Site
North Little Rock, Arkansas, United States
Ironwood Investigational Site
Chula Vista, California, United States
Ironwood Investigational Site
Los Angeles, California, United States
Ironwood Investigational Site
Ventura, California, United States
Ironwood Investigational Site
Miami, Florida, United States
Ironwood Investigational Site
Tampa, Florida, United States
Ironwood Investigational Site
Urbana, Illinois, United States
...and 12 more locations